医学
声动力疗法
内科学
肿瘤科
癌症研究
胶质母细胞瘤
放射科
临床试验
病理
作者
Nader Sanai,A-C. Tien,Artak Tovmasyan,Y. H. Chang,T. Margaryan,K Hendrickson,Jennifer M. Eschbacher,Wan-Hee Yoo,John K. Harmon,C. Chad Quarles,Lea M. Alhilali,Igor J. Barani,Surinder Kumar Mehta,Zaman Mirzadeh
标识
DOI:10.1016/j.annonc.2021.08.011
摘要
5-aminoleveulinic acid sonodynamic therapy (5-ALA SDT) is a drug-device strategy that exploits the metabolic liabilities of cancer. Following systemic administration of 5-ALA, incomplete tumor metabolism leads to accumulation of a photosensitive intermediary, protoporphyrin-IX (PpIX). Activation of PpIX by non-invasive, non-ablative magnetic resonance-guided focused ultrasound (MRgFUS) induces cytotoxic reactive oxygen species and tumor cell death. This first-in-human phase 0/1 study investigates the feasibility, safety, and biological effects of 5-ALA SDT in recurrent glioblastoma patients (GBM).
科研通智能强力驱动
Strongly Powered by AbleSci AI